1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Harry E. Bovay, Jr. Foundation Annual Symposium on Aging Research Pitch Competition 2026" is currently closed and not accepting applications.
Harry E. Bovay, Jr. Foundation Annual Symposium on Aging Research Pitch Competition 2026 is sponsored by UTHealth Houston Institute on Aging. This competition awards grants to support pilot studies in aging research, aimed at faculty who have not previously received support through this program.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Faculty at UTHealth Houston who have not previously received support through this program. Confirm the full requirements in the official notice before applying.
The current listing shows $7,500 - $15,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was August 15, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Harry E. Bovay, Jr. Foundation Annual Symposium on Aging Research Pitch Competition 2026 is funded by UTHealth Houston Institute on Aging. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Texas. If your organization operates elsewhere, check the official notice for location requirements.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Seven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read article